These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 7273593)

  • 21. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereoselective disposition of propranolol in rabbits. Role of presystemic organs and dose.
    Marier JF; Pichette V; du Souich P
    Drug Metab Dispos; 1998 Feb; 26(2):164-9. PubMed ID: 9456303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
    Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1985 May; 233(2):277-84. PubMed ID: 3999018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
    Bai SA; Wilson MJ; Walle UK; Walle T
    J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 27. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats.
    Terao N; Shen DD
    J Pharmacokinet Biopharm; 1984 Oct; 12(5):479-93. PubMed ID: 6520744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.
    Evans GH; Shand DG
    Clin Pharmacol Ther; 1973; 14(4):494-500. PubMed ID: 4723256
    [No Abstract]   [Full Text] [Related]  

  • 30. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relative bioavailability of a commercial propranolol hydrochloride tablet in man.
    Roscoe R; Cooper J; Wilson TW; Joshi NN; Midha KK
    Biopharm Drug Dispos; 1982; 3(2):105-14. PubMed ID: 7104460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of age on the hepatic clearance of propranolol in rats.
    Iwamoto K; Watanabe J; Araki K; Deguchi N; Sugiyama H
    J Pharm Pharmacol; 1985 Jul; 37(7):466-70. PubMed ID: 2863348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereoselective hydrolysis of O-isovaleryl propranolol and its influence on the clearance of propranolol after oral administration.
    Shameem M; Imai T; Yoshigae Y; Sparreboom A; Otagiri M
    J Pharm Sci; 1994 Dec; 83(12):1754-7. PubMed ID: 7891307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of propranolol isomers and their relationships with beta adrenoceptor blocking activity in rabbits administered with dl-propranolol.
    Kawashima K; Ishikawa H
    J Pharmacol Exp Ther; 1980 Jun; 213(3):628-31. PubMed ID: 6110769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
    Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
    Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction between oral hydralazine and propranolol. II. Assessment of altered splanchnic blood flow as the determinant of altered presystemic extraction.
    Corbett H; Cahill CM; Heinzow B; Harrison PM; Byrne AJ; McLean AJ
    J Pharmacol Exp Ther; 1986 Nov; 239(2):517-21. PubMed ID: 3772806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saturable first-pass kinetics of propranolol.
    Keller F; Kunzendorf U; Walz G; Haller H; Offermann G
    J Clin Pharmacol; 1989 Mar; 29(3):240-5. PubMed ID: 2723110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of aging on the stereoselective pharmacokinetics of propranolol in the rat.
    Vermeulen AM; Belpaire FM; Moerman E; de Smet F; Bogaert MG
    Chirality; 1992; 4(2):73-9. PubMed ID: 1616826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Propranolol absorption in untreated coeliac disease.
    Sandle GI; Ward A; Rawlins MD; Record CO
    Clin Sci (Lond); 1982 Jul; 63(1):81-5. PubMed ID: 7083769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.